Journal
VACCINE
Volume 28, Issue 1, Pages 261-269Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.09.085
Keywords
Tick subunit vaccine development; Synthetic peptide; Immuno-histochemistry; Cross-reactivity
Categories
Funding
- Agriculture, Forestry and Natural Resources (RFPP) of the North-South Centre, Zurich, Switzerland
Ask authors/readers for more resources
The BM86 antigen. originally identified in Rhipicephalus (Boophilus) microplus, is the basis of the only commercialized anti-tick vaccine The long-term goal of our study is to improve BM86 based vaccines by induction of high levels of tick gut binding antibodies that are also cross-reactive with a range of BM86 homologues expressed in other important tick species. Here we have used a BD86 derived synthetic peptide, BD86-3, to raise a series of mouse monoclonal antibodies One of these mAbs, named 12 1. recognized BM86 homologues in immuno-histochemical analyses in four out of five tick species including R. (B) microplus, Rhipicephalus (Boophilus) decoloratus. Hyalomma anatohcum anatolicum and Rhipicephalus appendiculatus Our results indicate that broadly cross-reactive tick gut binding antibodies can be induced after immunization with a synthetic peptide derived from the protein BD86 (C) 2009 Elsevier Ltd All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available